Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: Bellevue, Nebraska 25 trials found
New Search
Filter
Trial Phase
Study Type
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
PHASE2, PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
GEMINI-NSCLC: NSCLC Biomarker Study
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
N/AOBSERVATIONAL Fort Smith, Arkansas +4 more
RECRUITING
Comprehensive Outcomes for After Cancer Health
NAINTERVENTIONAL Gainesville, Florida +4 more
RECRUITING
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
PHASE2INTERVENTIONAL Tampa, Florida +4 more
RECRUITING
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
NAINTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
PHASE2INTERVENTIONAL Beverly Hills, California +4 more
RECRUITING
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
PHASE3INTERVENTIONAL Loma Linda, California +4 more
RECRUITING
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
PHASE3INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
PHASE1INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NAINTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Blood Markers of Early Pancreas Cancer
N/AOBSERVATIONAL Omaha, Nebraska
RECRUITING
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
PHASE2INTERVENTIONAL Mobile, Alabama +4 more
RECRUITING
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
PHASE2INTERVENTIONAL Orange, California +4 more
RECRUITING
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
PHASE2INTERVENTIONAL Little Rock, Arkansas +4 more
RECRUITING
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
PHASE1, PHASE2INTERVENTIONAL Duarte, California +4 more
RECRUITING
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
PHASE1INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
PHASE2INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
PHASE1INTERVENTIONAL Duarte, California +4 more
RECRUITING
Pancreatic Cancer Early Detection Consortium
N/AOBSERVATIONAL Phoenix, Arizona +4 more
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type